From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Oct 25

PMID 34692534

Citations 4

Authors

Giuseppe A Palumbo

Sara Galimberti

Wilma Barcellini

Daniela Cilloni

Nicola Di Renzo

Elena Maria Elli

Carlo Finelli

Luca Maurillo

Alessandra Ricco

Pellegrino Musto

Rodolfo Russo

Roberto Latagliata

Affiliations

Soon will be listed here.

Abstract

Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, with the aim to reduce iron overload (IOL) and prevent organ damage. This therapeutic approach is already widely used in thalassemic patients and in low-risk Myelodysplastic Syndrome (MDS) patients. More recently, ICT has been proposed for high-risk MDS, especially when an allogeneic bone marrow transplantation has been planned. Furthermore, other hematological and hereditary disorders, characterized by considerable transfusion support to manage anemia, could benefit from this therapy. Meanwhile, data accumulated on how iron toxicity could exacerbate anemia and other clinical comorbidities due to oxidative stress radical oxygen species (ROS) mediated by free iron species. Taking all into consideration, together with the availability of approved oral iron chelators, we envision a larger use of ICT in the near future. The aim of this review is to better identify those non-thalassemic patients who can benefit from ICT and give practical tips for management of this therapeutic strategy.

Citing Articles

Time-dependent effects of hypoxia on cell metabolism, signaling, and iron homeostasis in the hematopoietic progenitor model KG1a.

Nahoui-Zarouri I, Leger C, El Samra G, Cottet-Rousselle C, Moulis J FEBS Open Bio. 2022; 13(7):1291-1308.

PMID: 36416440 PMC: 10315738. DOI: 10.1002/2211-5463.13527.

Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes.

Rozema J, van Asten I, Kwant B, Kibbelaar R, Veeger N, de Wit H Eur J Haematol. 2022; 109(6):772-778.

PMID: 36130872 PMC: 9828450. DOI: 10.1111/ejh.13865.

Advances in Evaluation of Antioxidant and Toxicological Properties of Mart. in Model.

Salazar G, Ecker A, Adefegha S, Martins da Costa J Foods. 2022; 11(15).

PMID: 35954004 PMC: 9368094. DOI: 10.3390/foods11152236.

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Polverelli N, Farina M, DAdda M, Damiani E, Grazioli L, Leoni A Cells. 2022; 11(3).

PMID: 35159362 PMC: 8834299. DOI: 10.3390/cells11030553.

References

Fisher D, Malkova O, Engle E, Miner C, Fulbright M, Behbehani G . Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2016; 31(9):1962-1974. PMC: 5540814. DOI: 10.1038/leu.2016.377. View

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

Vinchi F, Hell S, Platzbecker U . Controversies on the Consequences of Iron Overload and Chelation in MDS. Hemasphere. 2020; 4(3):e357. PMC: 7306315. DOI: 10.1097/HS9.0000000000000357. View

Porter J, Lin K, Beris P, Forni G, Taher A, Habr D . Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011; 87(4):338-48. PMC: 3229702. DOI: 10.1111/j.1600-0609.2011.01660.x. View

Quinn C, Johnson V, Kim H, Trachtenberg F, Vogiatzi M, Kwiatkowski J . Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011; 153(1):111-7. PMC: 4250090. DOI: 10.1111/j.1365-2141.2010.08477.x. View

Cappellini M, Taher A . Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009; 122(2-3):165-73. DOI: 10.1159/000243801. View

Pawelec K, Salamonowicz M, Panasiuk A, Leszczynska E, Krawczuk-Rybak M, Demkow U . Influence of Iron Overload on Immunosuppressive Therapy in Children with Severe Aplastic Anemia. Adv Exp Med Biol. 2015; 866:83-9. DOI: 10.1007/5584_2015_148. View

Al-Ali H, Griesshammer M, Foltz L, Palumbo G, Martino B, Palandri F . Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020; 189(5):888-903. DOI: 10.1111/bjh.16462. View

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, cermak J, Del Canizo C . Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-64. PMC: 3811170. DOI: 10.1182/blood-2013-03-492884. View

10.

Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J . Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Rev. 2016; 30(5):349-56. DOI: 10.1016/j.blre.2016.04.003. View

11.

Greenberg P, Stone R, Al-Kali A, Barta S, Bejar R, Bennett J . Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(1):60-87. DOI: 10.6004/jnccn.2017.0007. View

12.

Tefferi A, Lasho T, Jimma T, Finke C, Gangat N, Vaidya R . One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012; 87(1):25-33. PMC: 3538387. DOI: 10.1016/j.mayocp.2011.11.001. View

13.

Gattermann N . Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2017; 107(1):55-63. DOI: 10.1007/s12185-017-2367-1. View

14.

Cetin T, Oktenli C, Ozgurtas T, Yenicesu M, Sanisoglu S, Oguz Y . Renal tubular dysfunction in beta-thalassemia minor. Am J Kidney Dis. 2003; 42(6):1164-8. DOI: 10.1053/j.ajkd.2003.08.016. View

15.

Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N . Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011; 6(8):e23109. PMC: 3158762. DOI: 10.1371/journal.pone.0023109. View

16.

Taher A, Origa R, Perrotta S, Kourakli A, Ruffo G, Kattamis A . New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017; 92(5):420-428. PMC: 6585741. DOI: 10.1002/ajh.24668. View

17.

Elli E, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E . Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study). Br J Haematol. 2019; 186(5):e123-e126. DOI: 10.1111/bjh.15964. View

18.

Liu H, Yang N, Meng S, Zhang Y, Zhang H, Zhang W . Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. Clin Exp Med. 2019; 20(1):1-9. DOI: 10.1007/s10238-019-00592-5. View

19.

Leitch H . Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2010; 25(1):17-31. DOI: 10.1016/j.blre.2010.09.003. View

20.

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa E . Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020; 172(8):513-522. DOI: 10.7326/M19-0916. View